Forefront Analytics, LLC Annexon, Inc. Transaction History

Forefront Analytics, LLC

$89.4 Million
Q2 2025

A detailed history of Forefront Analytics, LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Forefront Analytics, LLC holds 27,575 shares of ANNX stock, worth $86,861. This represents 0.07% of its overall portfolio holdings.

Number of Shares

27,575

Holding current value

$86,861

% of portfolio

0.07%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.38 - $2.73 $38,053 - $75,279	27,575 New	27,575 $66,000
Q1 2025 May 13, 2025	BUY	$1.93 - $5.5 $23,464 - $66,869	12,158 Added 73.99%	28,591 $55,000
Q4 2024 Feb 13, 2025	BUY	$4.44 - $7.63 $26,418 - $45,398	5,950 Added 56.76%	16,433 $84,000
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $25,233 - $40,464	-5,620 Reduced 34.9%	10,483 $62,000
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $5,564 - $8,725	1,285 Added 8.67%	16,103 $78,000
Q1 2024 May 15, 2024	SELL	$4.03 - $7.81 $66,341 - $128,568	-16,462 Reduced 52.63%	14,818 $106,000
Q4 2023 Feb 13, 2024	SELL	$1.63 - $4.63 $652 - $1,852	-400 Reduced 1.26%	31,280 $142,000
Q3 2023 Nov 07, 2023	BUY	$2.13 - $3.84 $10,415 - $18,777	4,890 Added 18.25%	31,680 $74,000
Q2 2023 Aug 11, 2023	BUY	$2.1 - $6.37 $24,231 - $73,503	11,539 Added 75.66%	26,790 $94,000
Q1 2023 May 11, 2023	SELL	$3.74 - $7.46 $766 - $1,529	-205 Reduced 1.33%	15,251 $58,000
Q4 2022 Feb 13, 2023	SELL	$4.56 - $6.61 $2,731 - $3,959	-599 Reduced 3.73%	15,456 $79,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.63 $18,112 - $32,022	-4,830 Reduced 23.13%	16,055 $98,000
Q2 2022 Aug 10, 2022	SELL	$2.11 - $4.06 $2,954 - $5,683	-1,400 Reduced 6.28%	20,885 $77,000
Q1 2022 May 09, 2022	BUY	$2.73 - $11.94 $60,838 - $266,082	22,285 New	22,285 $63,000

Others Institutions Holding ANNX

# of Institutions

142

Shares Held

96.5M

Call Options Held

Put Options Held

63.4K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $150M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Forefront Analytics, LLC with notifications on news.

Account

Forefront Analytics, LLC Annexon, Inc. Transaction History